GHSI vs. CLSN, ACST, KRON, CASI, NBRV, GANX, EGRX, NXTC, CLNN, and OCUP
Should you be buying Guardion Health Sciences stock or one of its competitors? The main competitors of Guardion Health Sciences include Imunon (CLSN), Acasti Pharma (ACST), Kronos Bio (KRON), CASI Pharmaceuticals (CASI), Nabriva Therapeutics (NBRV), Gain Therapeutics (GANX), Eagle Pharmaceuticals (EGRX), NextCure (NXTC), Clene (CLNN), and Ocuphire Pharma (OCUP). These companies are all part of the "medical" sector.
Guardion Health Sciences (NASDAQ:GHSI) and Imunon (NASDAQ:CLSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.
In the previous week, Guardion Health Sciences had 2 more articles in the media than Imunon. MarketBeat recorded 2 mentions for Guardion Health Sciences and 0 mentions for Imunon. Guardion Health Sciences' average media sentiment score of 0.25 beat Imunon's score of 0.00 indicating that Guardion Health Sciences is being referred to more favorably in the media.
Guardion Health Sciences has higher revenue and earnings than Imunon.
Guardion Health Sciences has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Imunon has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.
Guardion Health Sciences has a net margin of -16.69% compared to Imunon's net margin of -5,229.80%. Imunon's return on equity of -50.18% beat Guardion Health Sciences' return on equity.
20.2% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 13.0% of Imunon shares are held by institutional investors. 1.3% of Guardion Health Sciences shares are held by company insiders. Comparatively, 4.7% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Imunon received 325 more outperform votes than Guardion Health Sciences when rated by MarketBeat users. However, 67.39% of users gave Guardion Health Sciences an outperform vote while only 59.36% of users gave Imunon an outperform vote.
Summary
Guardion Health Sciences beats Imunon on 7 of the 12 factors compared between the two stocks.
Get Guardion Health Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GHSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardion Health Sciences Competitors List
Related Companies and Tools
